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Prolonged Cannabidiol Treatment Effects
on Hippocampal Subfield Volumes
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Jennifer H. Martin,3,4 Murat Yücel,2 and Nadia Solowij1,4,*
Abstract
Introduction: Chronic cannabis use is associated with neuroanatomical alterations in the hippocampus. While
adverse impacts of cannabis use are generally attributed to D9-tetrahydrocannabinol, emerging naturalistic ev-
idence suggests cannabidiol (CBD) is neuroprotective and may ameliorate brain harms associated with cannabis
use, including protection from hippocampal volume loss. This study examined whether prolonged administra-
tion of CBD to regular cannabis users within the community could reverse or reduce the characteristic hippo-
campal harms associated with chronic cannabis use.
Materials and Methods: Eighteen regular cannabis users participated in an *10-week open-label pragmatic
trial involving daily oral administration of 200 mg CBD, with no change to their ongoing cannabis use requested.
Participants were assessed at baseline and post-CBD treatment using structural magnetic resonance imaging.
Automated longitudinal hippocampal segmentation was performed to assess volumetric change over the
whole hippocampus and within 12 subfields.
Results: No change was observed in left or right hippocampus as a whole. However, left subicular complex (par-
asubiculum, presubiculum, and subiculum) volume significantly increased from baseline to post-treatment
( p = 0.017 uncorrected) by 1.58% (Cohen’s d = 0.63; 2.83% in parasubiculum). Heavy cannabis users demonstrated
marked growth in the left subicular complex, predominantly within the presubiculum, and right cornu ammonis
(CA)1 compared to lighter users. Associations between greater right subicular complex and total hippocampal
volume and higher plasma CBD concentration were evident, particularly in heavy users.
Conclusions: Our findings suggest a restorative effect of CBD on the subicular and CA1 subfields in current can-
nabis users, especially those with greater lifetime exposure to cannabis. While replication is required in a larger,
placebo-controlled trial, these findings support a protective role of CBD against brain structural harms conferred
by chronic cannabis use. Furthermore, these outcomes suggest that CBD may be a useful adjunct in treatments
for cannabis dependence and may be therapeutic for a range of clinical disorders characterized by hippocampal
pathology (e.g., schizophrenia, Alzheimer’s disease, and major depressive disorder).
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Regular and prolonged cannabis use has been associated
with morphological1,2 and functional brain changes,2–4
cognitive impairment,5 and increased risk of adverse
mental health outcomes, including the precipitation of
psychotic symptoms and disorders.6,7 Neuroimaging ev-
idence has consistently identified the hippocampus, a
subcortical brain region critically involved in learning
and memory and implicated in psychopathology, as a
particular locus of compromise.1,2 Long-term heavy can-
nabis users have demonstrated reduced hippocampal
volume8,9 and gray matter density10 compared to non-
user controls, with some evidence for greater volume
loss resulting from greater exposure to cannabis.1 Alter-
ations to hippocampal shape,11 neurochemistry,8 and
structural12 and functional connectivity13 in chronic
cannabis users have also been reported. Recently, we
showed that volumetric reduction of specific hippo-
campal subfields (cornu ammonis [CA]1–4 and den-
tate gyrus [DG]) was sensitive to cannabis dependence,
with an inverse correlation between greater lifetime can-
nabis exposure and subfield volumes in dependent, but
not nondependent users.14
Cannabinoid type 1 receptors (CB1Rs) are abundant
throughout the brain, but occur in high density in specific
regions, including the hippocampus.15 Cannabis-related
neurobiological, cognitive, and psychological harms
are generally ascribed to D9-tetrahydrocannabinol
(THC), the primary psychoactive constituent of can-
nabis, which is a partial agonist at CB1Rs.16,17 Acute
administration of THC to humans dose-dependently
transiently increases anxiety, impairs cognition, and
induces a range of positive and negative psychotic-
like symptoms, including paranoia, delusions, and
conceptual disorganization.18–20 While the precise
mechanisms underlying these effects are not well un-
derstood, animal studies have shown that THC accu-
mulates in neurons,21 with long-term exposure to
THC resulting in neurotoxic changes in hippocampal
microstructure.22 Conversely, cannabidiol (CBD) is
the second most abundant cannabinoid in cannabis
and has purported neuroprotective,23 anxiolytic,24
and antipsychotic25 properties. Acutely administered,
CBD exerts opposing effects to THC upon activation
of specific brain regions, including the hippocam-
pus,26 and ameliorates the induction of hippocampal-
dependent cognitive impairment and psychotic-like
symptoms by THC in healthy volunteers.27 CBD has
a low affinity for CB1Rs, yet demonstrates the capacity
to antagonize CB1R agonists, which may underlie its
functional antagonism of THC.28 Preclinical studies
have shown CBD to induce synaptic plasticity and
facilitate hippocampal neurogenesis,29,30 with some
evidence suggesting that the proneurogenic action
of CBD via the hippocampus may underlie its anxiolytic
effects.30 Although precise neurobiological mechanisms
by which CBD may promote neurogenesis remain un-
clear, modulation of endocannabinoids such as ananda-
mide through CB1Rs has been implicated.29,31
In recent years, increasingly potent strains of cannabis
containing high levels of THC and decreasing levels of
CBD have dominated the market, raising concerns for
greater THC-related harms in the community.7,32 Natu-
ralistic studies examining proportional exposure to THC
and CBD by hair analysis of chronic cannabis users
found that the presence of CBD in cannabis was as-
sociated with fewer psychotic-like symptoms,33,34
improved recognition memory,34 and increased hippo-
campal gray matter concentration.10 We have recently
shown apparent normalization of hippocampal volume
and n-acetylaspartate (NAA; a marker of hippocampal
neuronal integrity) levels in cannabis users regularly
smoking cannabis containing CBD, such that they
were indistinguishable from controls, while those exposed
to THC but not CBD, showed 11% smaller hippocampal
volumes and 15% lower NAA concentrations than con-
trols.8 These findings indicate CBD may protect against
neurobiological and psychological harms of regular can-
nabis use; however, the cross-sectional nature of these
studies precludes any inferences about directionality.
The possibility that prolonged administration of
CBD to cannabis users may protect against or reduce
THC-induced harms is intriguing. The hippocampus
is highly neuroplastic and volume growth has been
demonstrated following relatively brief interventions
(e.g., increase in hippocampal volume by 12% in pa-
tients with schizophrenia and 16% in healthy controls
following 12 weeks of aerobic exercise,35 indicating
this is an adequate timeframe to observe discernible
treatment effects in the hippocampus). Hence, this
study aimed to investigate whether prolonged adminis-
tration of CBD may reverse hippocampal volumetric
reduction typically observed in long-term, heavy can-
nabis users, but recruitment was broadened to enable
examination of effects of CBD treatment in a sample
with a range of cannabis experience. An *10-week
pragmatic, open-label trial was undertaken, in which
cannabis users within the community consumed 200 mg
CBD in capsule form daily, in the context of their ongo-
ing cannabis use. Structural magnetic resonance imaging
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(MRI) scans were completed at baseline and post-CBD
treatment. It was hypothesized that prolonged CBD
administration would result in increased hippocampal
volume at post-treatment, as subserved by growth in
specific subfields such as CA1, subiculum, and DG,
due to the high concentration of CB1Rs in these subre-
gions15 and their involvement in neurogenesis.36
Materials and Methods
Participants
Twenty regular cannabis users (at least once per month
for a minimum 6 months) aged 18–55 years were
recruited from the community through newspaper
and online advertisements. Exclusion criteria were cur-
rent or past regular (greater than once per month for
>6 months in the past 3 years) other illicit drug use or
dependence on or treatment-seeking for any substance
other than cannabis; history of synthetic cannabinoid
use; any neurological disorder or serious head injury;
psychiatric history (assessed by the Mini-International
Neuropsychiatric Interview Plus37) or medication use;
pregnancy or lack of contraception for female cannabis
users; and contraindications for MRI. Eighteen partic-
ipants completed both baseline and post-treatment
MRI scans and are reported in this study. Participants
provided informed written consent at baseline, post-
treatment, and each weekly session (see Procedure,
CBD administration, and dose section), and were reim-
bursed for their participation. The study was approved
by the University of Wollongong and Illawarra and
Shoalhaven Local Health District Health and Medical
Human Research Ethics Committee and registered as
a clinical trial (ISRCTN89498802).
Procedure, CBD administration, and dose
Further detail regarding the methodology of this
pragmatic trial is provided by Solowij et al. (compan-
ion article38). In brief, participants attended two
comprehensive testing sessions at the beginning
(baseline) and completion (post-treatment) of *10
weeks of CBD administration, involving MRI scan-
ning and other assessments (electroencephalography,
neuropsychological, and clinical, not reported in this
study). Participants were also required to attend brief
weekly appointments throughout the trial for moni-
toring of physiological and psychological well-being,
collection of blood and urine samples, and provision
of CBD capsules. Participants were not asked to make
any changes to their cannabis use patterns during the
trial, but were instructed to abstain from cannabis, al-
cohol, and other substances for a minimum 12 h be-
fore baseline and post-treatment testing sessions.
Participants were requested to abstain from use of il-
licit substances other than cannabis throughout the
trial and were advised urine drug screens would be
conducted to corroborate their self-report.38
At each weekly session, participants were provided
28 gelatin-coated capsules for oral administration con-
taining 50 mg of 99.5% pure crystalline CBD (of herbal
origin) solved in Miglyol 812 and Softisan 378 (Trigal
Pharma Ltd.; BioSynthesis Pharma Group Ltd.). Partic-
ipants were instructed to consume four capsules per
day (100 mg in the morning and 100 mg in the evening,
totaling 200 mg daily). This was selected as a ‘‘medium’’
dose in accordance with the range of therapeutic doses
reported in human studies (e.g., 800–1000 mg/day well
tolerated for up to 6 weeks in psychotic individuals39,40),
as well as for caution as no previous study had admin-
istered prolonged and relatively high doses of CBD to
current cannabis users. Participants received an SMS
text message each morning and evening reminding
them to consume their capsules. At each weekly session,
participants returned any unused capsules. Adherence
was measured by participants self-reporting the times
of any missed doses, using a Timeline Follow-Back Pro-
cedure,41 and corroborated by the number of capsules
returned.
Measures
Participants’ demographic data were obtained and
lifetime substance use quantified through structured
interview. The Timeline Follow-Back Procedure41
was employed at baseline and each subsequent session
to obtain a specific and accurate history of substance
use throughout the trial (cumulative cannabis, alcohol,
and tobacco use across the trial quantified). Cannabis
use was converted to standardized units of ‘‘cones’’
(1 joint = 3 cones; https://cannabissupport.com.au/
media/1593/timeline-followback.pdf) for quantifica-
tion. The Alcohol Use Disorders Identification
Test,42 Severity of Dependence Scale,43 and Cannabis
Withdrawal Scale44 were administered at baseline
and post-treatment to assess extent of alcohol con-
sumption, severity of cannabis dependence, and can-
nabis withdrawal symptoms from abstaining before the
test session. Blood and urine samples were collected at
each session to enable assay of CBD, THC, and THC
metabolite concentrations in plasma45 (following trial
completion), and for corroboration of self-reported
substance use by urine toxicology.
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Vocabulary and matrix reasoning subscales of the
Wechsler Abbreviated Scale of Intelligence46 were ad-
ministered at baseline to estimate full scale intelligence
quotient (IQ). Psychological symptoms of depression,
anxiety, and psychosis-proneness were assessed at
baseline and post-treatment using the following stan-
dardized measures: Beck Depression Inventory47; State
Trait Anxiety Index48; Community Assessment of
Psychic Experiences49; and Cannabis Experiences
Questionnaire (CEQ).50 Alternate forms of the Rey
Auditory Verbal Learning Test (RAVLT),51 demon-
strated to be sensitive to cannabis-related memory
impairment,52,53 were also administered at baseline
and post-treatment.
MRI acquisition and processing
Participants underwent structural MRI scans on a
3T Siemens Skyra with a 48-channel head and neck
coil using a T1-weighted gradient echo sequence,
MPRAGE, with 900 ms inversion time, TR/TE of
2300/2.1 ms, FA = 9, 192 slices 1 mm thick, field of
view = 256 · 256 mm, and matrix = 256 · 256, resulting
in 1.0 mm isotropic resolution and a total acquisition
time of 5 min and 26 sec. Participants also underwent
other MRI scan sequences not reported in this study.
T1-weighted images were processed using an automated
longitudinal hippocampal subfield segmentation proto-
col available through FreeSurfer neuroimaging software
version 6.0 (https://surfer.nmr.mgh.harvard.edu).54 This
technique relies upon the creation of an unbiased
subject-specific atlas, which each within-subject time
point is then reprocessed against, to reduce within-
subject variability.55 Furthermore, it has demonstrated
greater sensitivity in identifying subtle hippocampal
subregional changes than previous cross-sectional pro-
cessing methods.54 Images were first processed through
the longitudinal FreeSurfer stream,55 involving mo-
tion correction, skull stripping, intensity normaliza-
tion, Talairach transformation, atlas registration,
estimation of total intracranial volume, segmentation
of white and gray matter volumes, and parcellation of
subcortical structures, including the hippocampus.
Hippocampal segmentation was then applied, generat-
ing volumes for whole left and right hippocampi as well
as 12 subfields for each (parasubiculum, presubiculum,
subiculum, CA1, CA2/3, CA4, granule cells in the
molecular layer of the dentate gyrus [GC-ML-DG],
hippocampal-amygdala transition area, fimbria, molec-
ular layer of the dentate gyrus [ML-DG], hippocampal
fissure, and hippocampal tail), as depicted in Figure 1.
Statistical analyses
Statistical analyses were performed using SPSS version
21.0. Paired t-tests were conducted to assess volumetric
change from baseline to post-treatment for total left
and right hippocampal volumes and for the 12 sub-
fields comprising each. As this was a novel exploratory
pilot study in a small sample with no placebo control,
no adjustment was made for multiple comparisons.
Correlations examined associations between change in
hippocampal subregion volume (post-treatment minus
baseline volume, in mm3) and plasma CBD concentra-
tion, substance use parameters, psychological symptom,
and cognitive measures. Outcomes were further explored
by group (heavy versus light users, formulated by median
split on lifetime cannabis use) using repeated-measures
analysis of covariance (ANCOVA).
Results
Demographic, substance use, and psychological symp-
tom characteristics of the sample are summarized in
Table 1. Participants were predominantly young adult
males (median age 25 years; four females), most of
whom had completed some tertiary education. Partici-
pants had used cannabis regularly for a median of 5.17
years and at baseline were smoking cannabis a median
of 25.75 days per month. Cannabis frequency and quan-
tity measures did not significantly differ from baseline to
post-treatment, indicating that a consistent level of can-
nabis use was maintained by participants throughout the
trial. Most participants refrained from other illicit drug
use during the trial38 (the one exception was not an out-
lier on any hippocampal measures and his data were
retained in the analyses reported in this study). Median
CBD capsule adherence was 93.16% (range 68.67–
99.35%). Participants reported experiencing less euphoria
when smoking cannabis (lower CEQ Euphoria scores)
at post-treatment compared to baseline ( p = 0.001).
Changes in other psychological symptoms and cogni-
tion from baseline to post-treatment in this sample are
provided in Table 1 and reported in detail in a slightly
larger sample by Solowij et al.38
Mean and significance values of all hippocampal volu-
metric comparisons are presented in Table 2. Paired sam-
ples t-tests revealed no significant change in total left
or right hippocampal volume, nor in nine hippocampal
subfields. However, a significant increase in left parasu-
biculum volume was observed ( p = 0.035), with trend-
level increases in the left presubiculum ( p = 0.058) and
left subiculum ( p = 0.066). In addition, a trend toward
decreased volume in the right presubiculum was found
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( p = 0.056). Subsequently, to increase reliability, total vol-
umes of all subicular subfields (parasubiculum, presubic-
ulum, and subiculum) were pooled to create a ‘‘subicular
complex’’56,57 for each hemisphere. Paired samples t-tests
showed a significant increase in left subicular complex
volume ( p = 0.017; Cohen’s d = 0.63), but no change
in the right subicular complex ( p = 0.471; Cohen’s
d = 0.17). Changes in left and right subicular complex
and substructures are detailed in Table 3.
Correlations did not reveal any significant association
between left subicular complex or subregion volume
change and plasma CBD concentration, cumulative
CBD dose (calculated by number of capsules returned
by participants), or weeks of CBD treatment. Right
subicular complex volumetric change was significantly
correlated with plasma CBD concentration in the final
trial week (r = 0.62, p = 0.006), as well as a trend-level
association with mean CBD plasma concentration
over the trial (r = 0.45, p = 0.064), suggesting that
higher plasma CBD was associated with increased
growth in this area, despite the overall tendency to-
ward a decrease in this region from baseline to post-
FIG. 1. Cross-sectional slices of a T1-weighted image from one participant with automated segmentation
of hippocampal subfields overlaid. Coronal (top), axial (middle), and sagittal (bottom) views. CA, cornu
ammonis; GC-ML-DG, granule cells in the molecular layer of the dentate gyrus; HATA, hippocampal-amygdala
transition area; ML-DG, molecular layer of the dentate gyrus.
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treatment (Table 3). Age was not significantly corre-
lated with any subicular change, other than at trend
level in the left parasubiculum (r =0.43, p = 0.073),
indicating growth in this subregion was more pro-
nounced in younger participants, potentially implicat-
ing a role of brain maturation. Subicular complex or
subregion volume change did not significantly corre-
late with any substance use measures; importantly,
change in left subicular complex volume was not asso-
ciated with changes in alcohol use frequency or quan-
tity from baseline to post-treatment (both p > 0.601),
nor with cumulative quantity of cannabis, alcohol,
or cigarettes used over the trial (all p > 0.114). Left
subiculum volume was correlated with lifetime dura-
tion of cannabis use at baseline (r =0.54, p = 0.021;
trend for left subicular complex volume r =0.44,
p = 0.066), suggesting that smaller volumes at baseline
were associated with greater cannabis exposure, and
these normalized with CBD treatment. A significant in-
verse correlation was observed between change in right
subiculum volume and change in desired level of intoxi-
cation when smoking cannabis (scale 1–10 [what level of
intoxication do you usually like to reach?], which tended
to decrease from baseline to post-treatment: 7.14 vs. 6.97,
respectively; r =0.51, p = 0.031; trend level also for left
parasubiculum, r =0.43, p = 0.074; and left subicular
complex, r =0.42, p = 0.080). This suggests that in-
creased volume in these subicular regions was associated
with lesser desired level of ‘‘high’’ following CBD treat-
ment. No significant correlations between subicular com-
plex or subregion volumes and psychological symptom
or cognitive (RAVLT) measures were found.
Hippocampal volume change was further explored
between and within groups of heavy and light users
(median split on lifetime occasions of use, n = 9 [seven
male, eight right handed] each). Group differences in
cannabis use measures are presented in Table 4. Heavy
and light users significantly differed on lifetime cannabis
use, frequency and quantity of cannabis use at baseline
and post-treatment, cumulative cones smoked across
Table 1. Participant Demographic Data, Substance Use Measures, and Psychological Symptoms
at Baseline and Post-Treatment
Baseline Post-treatment t/Za p Effect size (d/r)
Age (years) 25.07 [20.56–46.83] —
Gender (male/female) 14/4 —
Handedness (left/right) 2/16 —
Education (years) 15.50 [11.00–17.50] —
IQ 114.44 (9.50) —
BMI 22.68 (2.96) —
Alcohol frequency (days/month) 3 [0–14] 6 [0–21] 1.95 0.051{ 0.33
Alcohol quantity (standard drinks/month) 15.50 [0–102] 27.50 [0–127.50] 1.22 0.222 0.20
Cumulative alcohol quantity across the trial (standard drinks) — 97.54 (75.76)
AUDIT 7.83 (5.10) 7.56 (4.97) 0.57 0.579 0.13
Regular smoker (yes/no) 8/10 —
Tobacco frequency (days/month) 0.50 [0–30] 5.50 [0–30] 1.48 0.138 0.25
Tobacco quantity (cigarettes/month) 2.50 [0–300] 8.75 [0–225] 0.66 0.508 0.11
Cannabis use
Age of first use (years) 17.09 (2.18) —
Age of onset regular use (years) 19.76 (2.11) —
Duration regular use (years) 5.17 [0.56–28.83] —
Estimated lifetime occasions of use (days) 1734 [141–8708] —
Past month frequency (days/month) 25.75 [2–30] 30.00 [3–30] 1.67 0.096{ 0.28
Past month quantity (cones) 177.50 [9–1125.00] 165 [8–1080.00] 0.60 0.551 0.10
Cumulative quantity across the trial (cones) — 438 [9.50–2195]
SDS 3.33 (2.47) 3.11 (2.19) 0.56 0.586 0.13
BDI 2 [0–14] 0.50 [0–12] 2.18 0.029* 0.36
STAI state 25.72 (5.15) 29.39 (8.24) 2.53 0.022* 0.67
STAI trait 32 [20–63] 32 [20–49] 1.52 0.129 0.25
CAPE total frequency 59.83 (10.18) 56.67 (9.13) 1.99 0.063{ 0.47
CAPE total distress 23.78 (16.40) 19.39 (12.68) 2.09 0.052{ 0.54
CEQ Euphoria 44.28 (7.78) 38.94 (6.81) 3.90 0.001* 0.93
RAVLT words recalled trials 1–5 52.59 (11.52) 55.41 (9.96) 1.88 0.079{ 0.47
Mean (SD) or median [range].
*p < 0.05.
{Trend-level significance.
aPaired samples t-test for normally distributed data; Wilcoxon signed-rank test for nonparametric data.
AUDIT, Alcohol Use Disorders Identification Test42; BDI, Beck Depression Inventory47; BMI, body mass index; CAPE, Community Assessment of Psy-
chic Experiences49; CEQ, Cannabis Experiences Questionnaire50; IQ, intelligence quotient; SD, standard deviation; SDS, Severity of Dependence Scale43;
STAI, State Trait Anxiety Index48; RAVLT, Rey Auditory Verbal Learning Task.51
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the trial, as well as years of education (median years:
heavy = 12.50 and light = 16.00; p = 0.003), but did
not differ in age ( p = 0.070) or IQ ( p = 0.056), any
plasma CBD concentration measure (all p > 0.063), nor
in alcohol or tobacco use or change over the trial (all
p > 0.136). Years of education was not correlated with
any hippocampal volume measure, so was not included
as a covariate in analyses. Heavy and light users did not
significantly differ on any hippocampal total or subre-
gion volume measure at baseline, other than at trend
level for the left fimbria ( p = 0.056). Repeated-measures
ANCOVAs were conducted with group as a between-
subjects factor and intracranial volume and cumulative
cones smoked across trial as covariates. As reported in
Table 5, no significant main effects of time were found
for any total hippocampal or subregion volume. How-
ever, significant time by group interactions were ob-
served in the left presubiculum ( p = 0.015) and right
CA1 ( p = 0.012). Figure 2a and 2b depict a marked in-
crease in volume in these subregions from baseline
to post-treatment in heavy users, yet a slight decrease
in lighter users, with both groups showing more simi-
lar volume post-treatment. Post hoc repeated mea-
sures ANCOVAs (controlling for cumulative cannabis
use across the trial) were performed within heavy and
light user groups separately. Significant main effects of
time were found only in heavy users for the left presu-
biculum ( p < 0.001; light users p = 0.80), left subicular
complex ( p = 0.003; light users p = 0.393), and trend
level for left subiculum ( p = 0.064; light users p =
0.344), indicating that the overall finding of increased
left subicular complex volume across the trial was
driven by the heavy user group. In addition, a signifi-
cant main effect of time was observed in heavy users
for the right CA1 ( p = 0.036; light users p = 0.577).
Exploratory correlations within heavy and light user
groups separately indicated associations with mean,
maximum, and final trial week plasma CBD concentra-
tions in heavy users only, for the right subicular complex
(CBD plasma: mean, r = 0.71, p = 0.032; maximum,
r = 0.68, p = 0.045; and final week, r= 0.82, p = 0.007),
right presubiculum (mean, r = 0.85, p = 0.003; maxi-
mum, r = 0.69, p = 0.040; and final week, r = 0.70,
p = 0.036), and right subiculum (final week, r = 0.68,
Table 2. Hippocampal Whole and Subfield Volumes (mm3)
at Baseline and Post-Treatment
Baseline Post-treatment p
Whole hippocampus
Left 3940.65 (333.06) 3962.13 (344.81) 0.180
Right 4127.15 (356.02) 4119.00 (375.98) 0.682
Subicular complex
Left 885.18 (81.89) 899.17 (85.15) 0.017*
Right 865.83 (99.15) 862.06 (102.53) 0.471
Parasubiculum
Left 64.36 (9.79) 66.18 (10.57) 0.035*
Right 64.97 (12.77) 64.29 (12.11) 0.418
Presubiculum
Left 342.48 (24.29) 347.77 (24.62) 0.058{
Right 334.71 (44.03) 330.36 (46.80) 0.056{
Subiculum
Left 478.33 (60.32) 485.22 (62.14) 0.066{
Right 466.15 (49.03) 467.40 (51.55) 0.697
CA1
Left 706.73 (73.16) 710.41 (77.20) 0.322
Right 750.62 (73.80) 754.35 (78.14) 0.380
CA2/3
Left 252.73 (42.57) 254.05 (42.93) 0.371
Right 284.33 (33.23) 283.08 (34.48) 0.533
CA4
Left 326.63 (41.35) 326.89 (40.76) 0.911
Right 353.30 (46.98) 352.50 (49.61) 0.760
GC-ML-DG
Left 360.98 (40.63) 360.80 (40.24) 0.935
Right 383.47 (45.14) 383.72 (48.72) 0.931
HATA
Left 62.54 (8.67) 62.76 (8.97) 0.812
Right 65.30 (6.82) 64.78 (7.02) 0.359
Fimbria
Left 96.37 (15.78) 97.26 (15.77) 0.482
Right 92.46 (23.75) 92.11 (23.58) 0.848
ML-DG
Left 667.82 (61.27) 670.34 (61.26) 0.450
Right 695.79 (60.06) 698.67 (64.04) 0.413
Hippocampal fissure
Left 155.92 (27.44) 157.35 (21.56) 0.725
Right 156.50 (18.92) 152.37 (20.76) 0.379
Hippocampal tail
Left 581.66 (62.20) 580.44 (63.11) 0.777
Right 636.05 (71.03) 627.74 (66.95) 0.126
Mean (SD) and paired t-test significance values. Subicular complex is
the sum of parasubiculum, presubiculum, and subiculum volumes.
*p < 0.05.
{Trend-level significance.
CA, cornu ammonis; GC-ML-DG, granule cells in the molecular layer of
the dentate gyrus; HATA, hippocampal-amygdaloid transition area; ML-
DG, molecular layer of the dentate gyrus.
Table 3. Percentage Change in Volume from Baseline
to Post-Treatment and Effect Sizes for Left
and Right Subicular Complex and Substructures
% change Effect size (d)
Left subicular complex 1.58 0.63
Left parasubiculum 2.83 0.55
Left presubiculum 1.54 0.48
Left subiculum 1.44 0.47
Right subicular complex 0.44 0.17
Right parasubiculum 1.05 0.20
Right presubiculum 1.30 0.51
Right subiculum 0.27 0.10
% change calculated as ([post-treatment volume–baseline volume]/
baseline volume) · 100.
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p = 0.042), indicating greater positive change (increased
volumes) with higher CBD concentrations (Fig. 3a, b).
In heavy users, final week CBD plasma was also corre-
lated with change in the whole right hippocampus
(r= 0.87, p = 0.002, as shown in Fig. 3c; p = 0.002 also
with removal of outlier) and in the right GC-ML-DG
(r= 0.70, p = 0.036), and trend level with right CA1
change (r = 0.63, p = 0.067), suggesting that growth in
these areas may be CBD treatment related.
Discussion
This study reports outcomes from the first trial of pro-
longed CBD treatment to cannabis users within the
community. We performed an automated longitudinal
hippocampal subfield segmentation to examine the po-
tential for chronic CBD administration to restore char-
acteristic hippocampal volumetric reduction in regular
cannabis users. We found an overall significant increase
of left subicular complex volume from baseline to post-
treatment, subserved by growth in the left parasubicu-
lum, presubiculum, and subiculum, with medium-large
effect sizes. We compared heavy and light users to ex-
plore the influence of prior cannabis exposure on CBD
treatment outcomes, finding that the increased left sub-
icular complex volume was driven by heavy users, par-
ticularly the marked growth that occurred in the left
presubiculum, which normalized post-treatment vol-
umes toward those observed in light users. Similarly,
only heavy users showed a significant increase in right
CA1 volume over the trial. Despite an overall trend to-
ward decreased right presubiculum volume from base-
line to post-treatment, significant associations between
higher plasma CBD concentration and increased growth
in this region were apparent, particularly in heavy users.
Plasma CBD concentration was also significantly corre-
lated with right subicular complex and total right hippo-
campal growth in heavy users.
These findings suggest a regionally specific restor-
ative effect of CBD upon the subicular and CA1 sub-
fields for heavy cannabis users, in the context of
ongoing and relatively consistent cannabis use during
the trial. The subicular subregions receive projections
from CA1 and function as the primary hippocampal
output structures, interfacing with the entorhinal cor-
tex and a range of cortical and subcortical sites.58
Functionally, CA1 neurons are critically involved in
the representation of temporal and spatial contextual
information and retrieval of episodic memory,59,60
while a dorsal-ventral functional segmentation has
been suggested for subicular subregions, whereby
dorsal subiculum is involved in spatial representation
and memory and ventral subiculum is involved in
hypothalamic–pituitary–adrenal regulation of stress,
anxiety, and reward.61
Subicular and CA1 subregions are implicated in path-
ophysiological models of various conditions.62 For ex-
ample, atrophy of the presubiculum, subiculum, and
CA1 are the earliest sites of hippocampal degeneration
in Alzheimer’s disease62–64; subiculum, presubiculum,
and right CA1 volume reduction have been demon-
strated in patients with schizophrenia65 and bipolar dis-
order;65–67 and subiculum and CA1 shape alterations
have been found in patients with major depressive disor-
der68,69 and schizophrenia70 relative to healthy controls.
Substantial evidence has revealed a pattern of progres-
sive hippocampal pathophysiology in patients with
schizophrenia, beginning with extracellular glutamate
dysregulation driving hypermetabolism in CA1, which
Table 4. Heavy and Light User Group Differences in Cannabis Use Measures
Heavy (n = 9) Light (n = 9) Z p
Duration regular use (years)
Baseline 6.53 [4.13–28.83] 3.39 [0.56–5.53] 3.18 < 0.001*
Estimated lifetime occasions of use (days)
Baseline 2608.50 [1734.00–8707.91] 452.00 [141.00–1448.00] 3.58 < 0.001*
Past month frequency (days/month)
Baseline 30.00 [9.00–30.00] 12.00 [2.00–30.00] 2.68 0.006*
Post-treatment 30.00 [13.00–30.00] 16.00 [3.00–30.00] 2.62 0.010*
Past month quantity (cones)
Baseline 375.00 [75.00–1125.00] 42.00 [9.00–463.75] 2.48 0.011*
Post-treatment 472.50 [58.50–1080.00] 55.00 [8.00–600.00] 2.56 0.008*
Cumulative quantity across the trial (cones)
Post-treatment 1282.00 [317.00–2195.00] 113.00 [9.50–815.00] 2.96 0.002*
Median [range] and Wilcoxon signed-rank test significance values.
*p < 0.05.
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precipitates attenuated psychotic symptoms, and ex-
tends to the subiculum during the transition to frank
psychosis.71–73 Longitudinal studies in ultra-high-risk
patients have demonstrated focal atrophy of CA1, at a
rate of 6% per year, differentiates those who progress
onto syndromal psychosis and those whose attenuated
psychotic symptom remit, with an extension of atrophy
to the subiculum then other subfields as the illness pro-
gresses.73,74 The rate of CA1 volume reduction specifi-
cally was found to predict worsening of symptom
severity over time,74 highlighting the importance of pre-
venting degeneration in this subregion. Furthermore, in
schizophrenia patients, subiculum volume reduction has
been associated with increased negative symptoms,65
and left presubiculum atrophy has been correlated
with impairments in episodic memory.75
Table 5. Adjusted Mean (Standard Error) of Hippocampal Whole and Subfield Volumes for Heavy and Light User Groups
Heavy (n = 9) Light (n = 9)
Time p Time by group pBaseline Post-treatment Baseline Post-treatment
Whole hippocampus
Left 3822.57 (60.57) 3872.15 (62.23) 4058.73 (60.57) 4052.10 (62.23) 0.197 0.198
Right 4025.95 (71.47) 4036.63 (68.91) 4228.35 (71.47) 4201.36 (68.91) 0.157 0.507
Subicular complex
Left 857.42 (20.96) 884.06 (22.77) 912.94 (20.96) 914.28 (22.77) 0.683 0.104
Right 871.28 (22.48) 865.40 (20.59) 860.38 (22.48) 858.71 (20.59) 0.254 0.780
Parasubiculum
Left 61.74 (3.30) 62.71 (3.74) 66.98 (3.30) 69.64 (3.74) 0.591 0.471
Right 66.50 (2.69) 65.56 (2.16) 63.44 (2.69) 63.03 (2.16) 0.195 0.322
Presubiculum
Left 336.55 (9.00) 350.70 (9.00) 348.41 (9.00) 344.83 (9.00) 0.752 0.015*
Right 336.50 (14.10) 334.65 (14.92) 332.93 (14.10) 326.07 (14.92) 0.341 0.436
Subiculum
Left 459.13 (15.99) 470.64 (16.76) 497.54 (16.76) 499.80 (16.76) 0.612 0.375
Right 468.29 (9.99) 465.20 (8.04) 464.01 (9.99) 469.61 (8.04) 0.977 0.829
CA1
Left 678.61 (15.72) 686.20 (16.18) 734.85 (15.72) 734.63 (16.18) 0.064{ 0.424
Right 714.39 (15.91) 731.81 (18.79) 786.84 (15.91) 776.89 (18.79) 0.119 0.012*
CA2/3
Left 238.72 (12.66) 240.03 (12.30) 266.74 (12.66) 268.08 (12.30) 0.390 0.995
Right 273.97 (9.03) 271.91 (8.77) 294.69 (9.03) 294.25 (8.77) 0.347 0.788
CA4
Left 313.37 (10.03) 313.59 (9.16) 339.90 (10.03) 340.20 (9.16) 0.409 0.990
Right 333.44 (12.77) 334.74 (13.22) 373.17 (12.77) 370.26 (13.22) 0.140 0.573
GC-ML-DG
Left 346.29 (9.99) 347.79 (9.24) 375.68 (9.99) 373.81 (9.24) 0.400 0.614
Right 364.66 (11.43) 368.37 (11.87) 402.29 (11.43) 399.07 (11.87) 0.085{ 0.378
HATA
Left 59.46 (2.85) 60.61 (3.46) 65.63 (2.85) 64.92 (3.46) 0.486 0.453
Right 63.67 (2.19) 62.73 (2.46) 66.94 (2.19) 66.83 (2.46) 0.523 0.631
Fimbria
Left 88.24 (4.83) 88.38 (4.77) 104.50 (4.83) 106.14 (4.77) 0.836 0.697
Right 86.02 (8.33) 81.41 (7.80) 98.90 (8.33) 102.81 (7.80) 0.201 0.055{
ML-DG
Left 647.81 (13.35) 655.02 (12.26) 687.84 (13.35) 685.65 (12.26) 0.164 0.304
Right 679.17 (11.95) 689.94 (13.56) 712.41 (11.95) 707.41 (13.56) 0.224 0.106
Hippocampal fissure
Left 160.18 (10.97) 157.78 (9.29) 151.66 (10.97) 156.91 (9.29) 0.365 0.501
Right 159.09 (8.39) 149.02 (8.84) 153.92 (8.39) 155.72 (8.84) 0.159 0.370
Hippocampal tail
Left 592.66 (25.66) 596.47 (25.11) 570.66 (25.66) 564.41 (25.11) 0.661 0.426
Right 639.38 (29.88) 630.33 (27.22) 632.72 (29.88) 625.14 (27.22) 0.416 0.926
Repeated measures ANCOVA main effect of time and time by group interactions, controlling for intracranial volume and cumulative cannabis use
(cones smoked) across the trial. Subicular complex is the sum of parasubiculum, presubiculum, and subiculum volumes.
*p < 0.05.
{Trend-level significance.
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Interestingly, 12 weeks of antipsychotic treatment
was found to increase subicular (but not CA1) volume
(encompassing all subicular subregions) by an average
32 mm3 (2.55%) in patients experiencing a first-episode
psychosis, while a healthy young adult control group
(of a similar age to the sample reported in this study;
mean [standard deviation]: 22.2 [4.9]) showed negli-
gible change in this region (0.53%) over the same pe-
riod.76 This suggests natural fluctuation in subicular
volume or the influence of ongoing brain maturation
across our similar trial length and participant sample
is unlikely, supporting a CBD treatment effect. Given
the parallels observed in schizophrenia pathophysiol-
ogy and neurobiological changes conferred by chronic
cannabis use,77,78 and interest in the antipsychotic
properties of CBD,25 our finding of volumetric restora-
tion in the subicular and CA1 regions is promising, and
this therapeutic indication for CBD may extend to
benefitting other clinical groups (e.g., schizophrenia).
The greater volumetric increase in heavy cannabis
users is consistent with psychological symptom and
cognitive outcomes from this trial, showing that depen-
dent users experienced a significantly greater reduction
in depressive and psychotic-like symptoms and im-
proved cognition compared to nondependent users
(reporting on n = 20 participants38). In addition, we re-
cently demonstrated protective effects of chronic CBD
treatment against the development of negative psychotic-
like symptoms in a preclinical model of schizophrenia,
with no effect in control animals.79 While a ceiling effect
FIG. 2. Time by group interaction for (a) left presubiculum (*p = 0.015) and (b) right CA1 (*p = 0.012) volume,
controlling for intracranial volume and cumulative cannabis use (cones smoked) across the trial. Error bars
represent standard error.
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may have occurred in lighter users, our findings never-
theless provide further support for the contention that
CBD may confer greater therapeutic effects in a more
compromised brain.
Our findings suggest a restorative effect of CBD on
hippocampal substructures in cannabis users, even
within the context of continued cannabis use. In the
absence of ongoing use, as might occur in a motivated
treatment-seeking sample, greater neurotherapeutic
benefit may be expected. During the trial, participants
reported feeling less high after using cannabis and this
was corroborated by significant reduction at post-
treatment on the CEQ Euphoria subscale. As such,
CBD may be a valuable adjunct to psychological treat-
ments for cannabis dependence. Furthermore, subjec-
tive ratings of preferred level of cannabis intoxication
were negatively associated with increased subicular re-
gion growth.
A critical limitation of this study was that it was a
pragmatic, open-label trial without a placebo control.
While it is unlikely that brain structural measures are
amenable to expectancy effects, our findings should
nevertheless be interpreted with caution. In addition,
the sample was relatively high-functioning, and some
participants’ cannabis use was infrequent. If thera-
peutic effects of CBD are more likely to manifest in
a disease state, this gives even greater credence to
our findings and stronger effects may be expected in
a more entrenched sample. As the majority of partic-
ipants were young adult males, the influence of ongo-
ing brain maturation must be considered and future
research should examine age effects as well as potential
sex differences in CBD treatment effects. That some hip-
pocampal subfield volume changes were associated with
plasma CBD concentrations supports the changes being
CBD treatment related. Nevertheless, replication in a
larger sample placebo-controlled trial is warranted.
The mechanisms underlying a restorative effect of
CBD on hippocampal subfields in cannabis users re-
main to be elucidated. While neurogenesis is plausible,
no change was observed in the DG, the primary hippo-
campal subregion implicated in neurogenesis. The po-
tential involvement of both CB1Rs and glutamate is
worthy of further investigation, given the high density
of cannabinoid receptors in the subicular complex and
CA1 regions,15 and evidence suggesting glutamatergic
dysregulation to be a driver of subicular and CA1 vol-
ume changes associated with psychosis.72,73 The dif-
ferential pattern of volume change observed across
left and right hippocampi is also of interest. While
FIG. 3. Significant associations in heavy users
between (a) mean plasma CBD concentration and
right presubiculum volume change; (b) mean
plasma CBD concentration and right subicular
complex volume change; and (c) final week
CBD plasma concentration and right total
hippocampal volume change. CBD, cannabidiol.
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the majority of studies examining cannabis-related
hippocampal pathophysiology which have reported
hemispheric lateralization effects found volume re-
duction to be more pronounced in the right hip-
pocampus,10,80,81 inverse associations between left
hippocampal volume and cannabis exposure (e.g.,
cumulative use9 and quantity per week82) have also
been reported. Mechanisms for hemispheric differ-
entiation remain unclear, and future research should
seek to examine potential lateralization effects in
CBD treatment response.
In conclusion, our findings are the first to demon-
strate an ameliorating effect of CBD treatment upon
brain structural harms characteristic of regular can-
nabis use. Furthermore, these results speak to the po-
tential for CBD treatment to restore hippocampal
pathology in a range of clinical populations (e.g.,
schizophrenia, Alzheimer’s disease, and major de-
pressive disorder).
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P, Martin JH, Yücel M, Solowij N (2018) Prolonged cannabidiol treat-
ment effects on hippocampal subfield volumes in current cannabis
users, Cannabis and Cannabinoid Research 3:1, 94–107, DOI: 10.1089/
can.2017.0047.
Abbreviations Used
ANCOVA¼ analysis of covariance
AUDIT¼Alcohol Use Disorders Identification Test
BDI¼ Beck Depression Inventory
BMI¼ body mass index
CA¼ cornu ammonis
CAPE¼Community Assessment of Psychic Experiences




GC-ML-DG¼ granule cells in the molecular layer of the
dentate gyrus
HATA¼ hippocampal-amygdaloid transition area
IQ¼ intelligence quotient
ML-DG¼molecular layer of the dentate gyrus
MRI¼magnetic resonance imaging
NAA¼ n-acetylaspartate
RAVLT¼ Rey Auditory Verbal Learning Test
SD¼ standard deviation
SDS¼ Severity of Dependence Scale
STAI¼ State Trait Anxiety Index
THC¼D9-tetrahydrocannabinol
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